TRIBE-2: A phase III, randomized, openlabel, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group

Chemotherapy plus bevacizumab is a standard first-line treatment for unresectable metastatic colorectal cancer patients. Different chemotherapy backbones may be chosen, including one to three drugs, based on patients’ general conditions and comorbidities, treatments’ objectives, and disease characteristics.